Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting
09 April 2022 - 6:55AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease, today
announced preclinical data at the 2022 American Association for
Cancer Research (AACR) Annual Meeting. This includes data from
SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC® platform,
and the company’s GADLEN platform.
“We have made excellent progress advancing compounds in our
preclinical pipeline,” said Taylor Schreiber, M.D., Ph.D., Chief
Executive Officer of Shattuck. “Data from our SL-9258 compound
indicate potent modulation of myeloid cells, T cells, and
cytokines, including IL-2, which collectively translated to
superior anti-tumor activity in comparison to TIGIT and PD-L1
antibodies in a preclinical model of PD-1 acquired resistance. In
addition, multiple compounds from our gamma delta T cell engager,
or GADLEN, platform have shown specific anti-tumor activity in
preclinical studies, which will help guide our lead candidate
selection and clinical development strategy. We look forward to
nominating our next clinical product candidate in 2022.”
Details of the presentations are as follows:
Abstract title: LIGHT (TNFSF14)
costimulation with TIGIT blockade broadens the activity of
checkpoint inhibitors (CPIs) into checkpoint inhibitor refractory
and resistant tumors through targeted myeloid cell and effector
lymphocyte activation
Shattuck presented preclinical data for SL-9258
(TIGIT-Fc-LIGHT), a bispecific fusion protein from its ARC
platform, demonstrating that SL-9258 simultaneously provides
checkpoint blockade to all tumor-expressed PVR ligands and broadens
immune costimulation by the TNF ligand known as LIGHT. LIGHT’s
ability to bind and activate CD8+ T and natural killer cells
through interactions with one of its receptors known as HVEM and
myeloid cells through interactions with its other receptor known as
LTbR, translates into strong anti-tumor responses in checkpoint
primary and acquired resistance murine tumor models, where TIGIT
blocking antibodies demonstrate no activity.
TIGIT-Fc-LIGHT was evaluated and well tolerated in non-human
primates at doses up to 40 mg/kg and similar on-target
pharmacodynamic activity was observed to what was characterized
preclinically in mice. Together, these results suggest that
TIGIT-Fc-LIGHT may provide clinical benefit to patients that are
refractory to conventional checkpoint blockade therapy.
Abstract title: Bispecific gamma/delta T cell engagers
containing butyrophilin 2A1/3A1 heterodimeric fusion protein
efficiently activate Vg9Vd2+ T cells and promote tumor cell
killing
Shattuck presented preclinical data highlighting the potential
of GADLENs to direct gamma delta T cells to kill tumor cells and in
the process, further elucidate tumor cell markers which are
important for the therapeutic activity of gamma delta T cell-based
therapies.
Shattuck’s bispecific GADLENs containing heterodimeric BTN2A1
and BTN3A1 extracellular domains fused via inert Fc linkers to scFv
domains, targeting CD19 or CD20 tumor-antigens, demonstrated an
ability to induce proliferation, degranulation, and cytokine
production in Vg9Vd2+ T cells with costimulation of a natural
cytotoxicity receptor or T cell costimulatory receptor. Further,
CD19 and CD20 directed GADLENs enhanced the specific killing of
lymphoma cells that express both antigen targets.
Additional meeting information can be found on the AACR website,
https://www.aacr.org. The posters will be available under Posters
on the Company’s website shortly after the event.
About Shattuck Labs, Inc.Shattuck Labs,
Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company
pioneering the development of bi-functional fusion proteins as a
new class of biologic medicine for the treatment of patients with
cancer and autoimmune disease. Compounds derived from Shattuck’s
proprietary Agonist Redirected Checkpoint, ARC®, platform
simultaneously inhibit checkpoint molecules and activate
costimulatory molecules within a single therapeutic. The company’s
SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the
CD47 immune checkpoint and simultaneously agonize the CD40 pathway,
is being evaluated in two Phase 1 trials. A second product
candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase
1 trial in solid tumors or lymphomas. Additionally, the company is
advancing a proprietary Gamma Delta T Cell Engager, GADLEN™,
platform, which is designed to bridge gamma delta T cells to tumor
antigens for the treatment of patients with cancer. Shattuck has
offices in both Austin, Texas and Durham, North
Carolina. For more information, please
visit: www.ShattuckLabs.com.
Investor Contact:Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Media Contact:Stephanie AscherManaging
DirectorStern Investor Relations,
Inc.Stephanie.ascher@sternir.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024